Overview
- Eli Lilly posted first-quarter revenue of $19.8 billion with 56% growth and raised its 2026 guidance to $82–$85 billion in sales and $35.50–$37.00 in non-GAAP EPS.
- Foundayo, an FDA-approved oral GLP-1 pill for obesity that does not require food or water timing, is positioned to expand access beyond injections.
- A single FDA adverse-event entry noted serious liver failure in a patient treated with Foundayo, and Lilly said it determined the case was not reasonably related to the drug.
- Shares dipped briefly after the report, while Wolfe Research and RBC reiterated positive views, and Morgan Stanley and Cantor Fitzgerald lifted price targets after the Q1 update.
- Mounjaro and Zepbound demand drove results, and Lilly pointed to pipeline and deal activity, including acquisitions such as Ajax and reported gains for Jaypirca and retatrutide.